1. Pink Sheet
  2. >>Geography

J&J Consumer Makes 'Aggressive' Shift In Digital Sales To Drive Growth

 
• By Malcolm Spicer

When J&J CEO Gorsky says, "We're not just sitting back, we're making aggressive moves in areas such as e-commerce, investments in that shift," his words are music to analysts' ears. J&J has OTC drug and other consumer health brands to drive growth, but it's missing the digital piece, they say.

Johnson & Johnson didn't disappoint analysts by announcing, following flat consumer health revenues in the fourth quarter, it is investing in making its segment more competitive in a market swinging more toward online sales.

"The shift to e-commerce, shift in some cases to more natural brands, digital types of brands," says CEO Alex Gorsky, "have been more secular in nature and have

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from International

More from Geography

Trump Administration Push For Dismissal, Transfer Of Mifepristone Case Leaves Overhang For Pharma

 
• By Sarah Karlin-Smith

The Trump Administration requested a dismissal or transfer of a lawsuit seeking to tighten the safety requirements for the abortion pill mifepristone on procedural grounds, which still leaves the administration's position on the case's merits unclear.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.

Viatris Agrees To $335m Opioid Settlement Ending US State, Local Government Cases

 
• By Dean Rudge

Viatris joined Hikma and Amneal, in signing agreements for cash settlements that resolve allegations its practices fueled the US’ deadly opioid epidemic.